Actively Recruiting
RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL
Led by Zhejiang Cancer Hospital · Updated on 2024-11-18
44
Participants Needed
1
Research Sites
294 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, single-arm, multicenter clinical study to evaluate the efficacy and safety of chidamide, rituximab combined with lenalidomide sequential immunochemotherapy in the treatment of newly diagnosed elderly double-expressor diffuse large B-cell lymphoma.
CONDITIONS
Official Title
RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Untreated diffuse large B-cell lymphoma patients confirmed by tissue analysis
- Immunohistochemistry showing positive MYC (≥40%) and BCL2 (≥50%) protein expression
- Age over 70 years, or age 65 years or older with an ECOG score of 2 or higher, both male and female
- Having at least one measurable lesion: lymphadenopathy >1.5 cm or extranodal lesion >1.0 cm with measurable diameters
- ECOG performance status of 3 or less
- Expected survival time of 3 months or more
- Voluntary participation with full understanding and signed informed consent
- Willingness and ability to complete all study procedures
You will not qualify if you...
- Pathological subtypes including PCNSL, PMBCL, EBV-positive DLBCL, and high-grade B-cell lymphoma
- Diagnosis accompanied by hemophagocytic syndrome
- Central nervous system involvement secondary to lymphoma
- Participation in other clinical studies or receiving study drugs less than 4 weeks after prior trial treatment
- HIV infection
- Major surgery within 28 days before study start
- Active infection requiring systemic anti-infective therapy within 14 days before study start
- Investigator judgment deeming patient unsuitable for study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022
Actively Recruiting
Research Team
C
Chen Xi
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here